by | Jul 1, 2026
Using biologic therapies as first-line systemic treatment for psoriasis: a cohort study following the target trial emulation framework using data from the British Association of Dermatologists Biologics and Immunomodulators RegisterPhan, D. B., Laws, P., Smith, C. H.,...
by | Jun 23, 2026
Melittin in AllergoOncology: From Honey Bee Venom to Anti-Cancer Therapeutic Innovation-An EAACI Position PaperJimenez-Rodriguez, T.-W., Ahmetaj, L., Alfaya Arias, T., Boni, E., Bugadze, L., Chauhan, J., De Las Vecillas, L., Ferastraoaru, D., Izquierdo, E.,...
by | Jun 4, 2026
Jagged1+ Tregs mediate lymphatic remodeling in tumor-draining lymph nodesXu, J. Z., Tsai, P. H., Lui, P. P. W., Wang, J. T., Aziz, H., Xie, B., Cho, I. J., Terranova Barberio, M., Li, C. Z., Stoker, K., Yu, H., Denton, A. E., Lawrence, T., Karagiannis, S. N. &...
by | May 8, 2026
HLA genotype, clinical and immunofluorescence findings of 30 patients with type VII collagen antibody positive subepidermal bullous diseaseBasra, R., Naderi, R., Yogarajah, S., Mee, J., Shaw, O., Watson, N., Cooney, J., Groves, R. W., Setterfield, J. & Tull, T., 8...
by | May 5, 2026
Serious infection risk with systemic treatments for psoriasis: A cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Bright, H. R. B., Smith, C. H., Laws, P., Reynolds, N. J., Phan, D. B., Lunt, M., Warren, R. B. &...